Prognostic Factors in Uterine Leiomyosarcoma: A Clinical and Histopathological Study of 143 Cases the Radiumhemmet Series 1936-1981

Larson, Benjamin T.; Silfverswärd, Claes; Nilsson, Bo; Pettersson, Folke

doi:10.3109/02841869009126543

Cited by 90 publications

(50 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent studies, tumor size was found to be a prognostic factor for stage I disease, and both 5 and 10-cm thresholds were proposed (9,(19)(20)(21). Moreover, in our study, the mean tumor size was statistically significantly larger in the LMS group (11.88±7.79) than in the AL and CL group (p=0.008).…”

Section: Discussionsupporting

confidence: 46%

Diagnostic and Prognostic Significance of p16, p53, and bcl-2 Expressions and Ki-67 Proliferation Index in Benign and Malignant Uterine Smooth Muscle Tumors

Akkalp¹,

Tetikkurt²,

Koy³

et al. 2017

Erciyes Med J

View full text Add to dashboard Cite

Objective: This study aimed to evaluate diagnostic parameters such as mitotic count and tumor size in; leiomyosarcomas (LMSs) and benign uterine smooth muscle tumors (USMTs) and to define the diagnostic value and prognostic significance of the Ki-67 proliferation index and p16, p53, and bcl-2 expressions by immunohistochemical (IHC) methods. Materials and Methods:In total, 44 cases diagnosed as LMS, atypical leiomyoma, or cellular leiomyoma at our pathology department from January 2010 to December 2015 were included. IHC staining was performed for bcl-2, p16, p53, and Ki-67 using standard techniques.Results: Tumor size and mitotic index were significant prognostic factors (p=0.008 and p=0.001, respectively). The rate of diffuse p16 expression was significantly higher in the LMS group than in the other LM group (p=0.001). A Ki-67 positivity rate of >10% (increased proliferation) was statistically significantly higher in the LMS group than in the benign USMT group (p=0.0001). No statistically significant difference was found between the LMS and benign USMT groups with respect to bcl-2 expression (p=0.892). Mitotic count and high Ki-67 expression (>%10) were statistically high in cases with relapse/ metastasis (+) (p=0.0001 and p=0.0002, respectively). Conclusion:In addition to histopathological findings (tumor size and mean mitotic count), diffuse p16 expression and p53 overexpression can be used to distinguish between benign and malignant USMTs. A high mitotic index [≥10/10 (high-power field)] and high Ki-67 expression (>10%) can serve as useful indicators for diagnosing LMS, distinguishing benign tumors, and predicting an aggressive clinical course.

show abstract

Section: Discussionsupporting

confidence: 46%

Diagnostic and Prognostic Significance of p16, p53, and bcl-2 Expressions and Ki-67 Proliferation Index in Benign and Malignant Uterine Smooth Muscle Tumors

Akkalp¹,

Tetikkurt²,

Koy³

et al. 2017

Erciyes Med J

View full text Add to dashboard Cite

show abstract

“…The contribution of other factors, including age at diagnosis, menopausal status and mitotic count, remains controversial [5, 9, 10]. An improved understanding of what affects CS prognosis would improve survival by facilitating the development of more effective, targeted therapies.…”

Section: Introductionmentioning

confidence: 99%

Prognoses and Prognostic Factors of Carcinosarcoma, Endometrial Stromal Sarcoma and Uterine Leiomyosarcoma: A Comparison with Uterine Endometrial Adenocarcinoma

et al. 2006

View full text Add to dashboard Cite

Aims: The aims of this study were to evaluate the factors affecting prognosis in patients with uterine sarcomas and to demonstrate that carcinosarcoma bears a similarity to high-grade endometrial carcinoma in terms of its prognosis and clinicopathological parameters. Methods: In June 2004, 17 Japanese institutions received questionnaires regarding uterine sarcomas. Study patients had uterine sarcomas initially treated at each institution between January 1990 and May 2004. Survival analyses and comparisons were performed by univariate methods. Patient data of 921 cases of endometrial adenocarcinoma were also analyzed and compared to the data with the uterine sarcomas. Results: One hundred twenty-one patients with uterine sarcomas were identified who met study eligibility criteria. In uterine sarcomas, carcinosarcoma had a worse prognosis than other sarcomas, but the difference was not significant (p = 0.302). In carcinosarcoma, significant differences were observed with age (p = 0.0388), stage (p < 0.01) and surgical procedure (with or without pelvic lymphadenectomy, p = 0.0316). In carcinosarcoma and G3 adenocarcinoma, no significant difference was identified with regard to overall survival in univariate (p = 0.191) and multivariate (p = 0.168) analyses. Conclusion: Our results demonstrate that the clinical behavior of carcinosarcoma strongly resembles that of G3 endometrial adenocarcinoma, setting it apart from other ‘pure’ uterine sarcomas.

show abstract

“…Differentiation from cervical fibroid is difficult unless supported by histopathology and immunohistochemical marker. Stage, menopausal status, mitotic count, tumour size, age are known to affect the prognosis of uterine leiomyosarcoma, 2,3 however there are too few cases to elaborate the criteria for predicting prognosis in cervical leiomyosarcoma.…”

Section: Discussionmentioning

confidence: 99%

A Rare Case of Leiomyosarcoma of Cervix and challenges in its management.

Mehra

Sidhu

Pandey³

et al. 2015

Int J Res Med Sci

View full text Add to dashboard Cite

Prognostic Factors in Uterine Leiomyosarcoma: A Clinical and Histopathological Study of 143 Cases the Radiumhemmet Series 1936-1981

Cited by 90 publications

References 15 publications

Diagnostic and Prognostic Significance of p16, p53, and bcl-2 Expressions and Ki-67 Proliferation Index in Benign and Malignant Uterine Smooth Muscle Tumors

Diagnostic and Prognostic Significance of p16, p53, and bcl-2 Expressions and Ki-67 Proliferation Index in Benign and Malignant Uterine Smooth Muscle Tumors

Prognoses and Prognostic Factors of Carcinosarcoma, Endometrial Stromal Sarcoma and Uterine Leiomyosarcoma: A Comparison with Uterine Endometrial Adenocarcinoma

A Rare Case of Leiomyosarcoma of Cervix and challenges in its management.

Contact Info

Product

Resources

About